GenOSept is a specific targeted research project (STREP) which uses a multidisciplinary fundamental genomics approach (gene expression, structural genomics, population genetics) to examine genetic predisposition to sepsis. Sepsis (life-threatening infection) is a major public health problem throughout Europe. In the USA in 1995 it cost $17 billion to treat 751,000 patients with severe sepsis, of whom 28.6% died. The Center for Disease Control suggests that sepsis-attributable mortality rates are rising. We hypothesize that susceptibility to expensive new treatments, and fatal outcomes from severe sepsis, are in part, genetically determined. GenOSept work packages will test this hypothesis using the following approach. We will use gene expression studies to define novel candidate genes including those controlling programmed cell death. The novel candidate genes so identified will then be analysed in subsequent epidemiologic studies of genetic predisposition to sepsis-related mortality and morbidity in European intensive care units. The European Society of Intensive Care Medicine (ESICM) will co-ordinate a consortium of leading experts in sepsis, genomics, genetic epidemiology, biometrics and genetic high-throughput genotyping to link this new science to patient-centred outcomes. GenOSept will provide important data on gender-related mortality and morbidity. It will have a major impact on diagnosis and treatment of European sepsis patients in subsequent therapeutic trials by targeting risk subpopulations and focussing expensive new treatments. GenOSept will standardise protocols for genotyping, facilitate application of new knowledge in functional and structural genomics, harmonize high-throughput genotyping and quality control between major European centres, and contribute to reducing sepsis-related mortality in European health care.
Call for proposal
See other projects for this call
Funding SchemeSTREP - Specific Targeted Research Project